New Joint Venture to Shake Up Immuno-Oncology in the UK

02/03/2016 - 3 minutes

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M.

cenyauri_horizon_biotech_uk_axxinityJust created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow.

The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, such as Novartis, GSK, Bristol-Myers Squibb and even some of the biotech players in the Human Microbiome.

Avvinity seems positioned as a serious contender, especially because of the expertise and technology of its founders.

Horizon is a Cambridge success story specializing in gene-editing services (like CRISPR) but also in oncology and drug development with their SuperCell lines.

This important expertise will now be combined with the Alphamer platform, an interesting technology owned by Centauri (which focus on infectious diseases).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!